

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. **(Currently Amended)** A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition comprising consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients comprising consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol; and

less than 1% (w/v) lipid;

0.5 to 2% (w/v) propylene glycol;

an antimicrobial agent; and,

a pH modifier,

wherein the composition further comprises less than 5% (w/v) of total propofol degradants when maintained at 40 °C for 4 weeks, and the composition is clear to the naked eye.

2 - 5. (Canceled)

6. **(Currently Amended)** The composition of Claim 1, wherein said polyethylene glycol comprises is polyethylene glycol 400, and wherein said excipients further comprise one or more compounds selected from the group consisting of citric acid, disodium edetate, metabisulfite, benzyl alcohol, propylene glycol, an antioxidant, a preservative, an antimicrobial agent, and a microbicidal.

7. (Canceled)

8. (Previously Presented) The composition of Claim 1, wherein:

a) said composition has a particle size diameter of between 25 and 200 nm;

b) said composition has a particle size diameter of between 50 and 100 nm; or

c) said composition forms particles of similar particle size.

9. (Previously Presented) The composition of Claim 1, wherein:

a) said composition does not support microbial growth; or

b) said composition is microbicidal.

10. (Canceled)

11. (Canceled)

12. (Canceled)

13.-24. (Canceled)

25. (Currently Amended) A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition comprising consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients comprising consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol;

0% to 1% (w/v) propylene glycol;

an antimicrobial agent;

a pH modifier;

and less than 1% (w/v) lipid, wherein the composition is clear to the naked eye.

26. (Currently Amended) The composition of Claim 25, wherein said excipients comprise consisting essentially of 8% (w/v) Poloxamer 188; 3% (w/v) polyethylene glycol 400; and 1% (w/v) propylene glycol, an antimicrobial agent, and a pH modifier.

27. (Previously Presented) The composition of Claim 1, wherein said composition is stored in a container having a means for dispensing the composition.

28-29. (Canceled)